Brian Yordy

Brian Yordy is a Principal at F-Prime Capital, the Boston- and Cambridge-based venture capital firm that invests across healthcare and technology (F-Prime is affiliated with the Fidelity/Johnson family of funds and is distinct from Fidelity's mutual-fund business). He joined F-Prime in 2018 and concentrates on the firm's biopharmaceutical and medical technology investing, drawing on a deep scientific background to evaluate early-stage therapeutics and platform companies.

Before entering venture capital, Yordy was an Engagement Manager at McKinsey & Company (roughly 2013–2018), where he advised pharmaceutical and medical technology clients on business development, R&D, and corporate strategy. That combination of scientific training and strategy consulting shapes how he underwrites companies — pairing an assessment of the underlying biology with a view on development strategy and commercial path.

Academically, Yordy holds a PhD in Immunology from Yale University (Yale School of Medicine) and a B.S. in Biochemistry from the University of Notre Dame. His immunology training is reflected in a portfolio weighted toward immuno-oncology, cell therapy, and immune-mediated and rare diseases.

Note on the source stub: F-Prime is an institutional venture capital firm rather than an angel network, and Yordy's current, publicly listed title is Principal (not Senior Associate). The corrected details above reflect F-Prime's own team page and multiple investor databases.

• Invests in early-stage life sciences — primarily seed and Series A biopharma and medtech companies.
• Sector concentration: biopharmaceuticals and medical technology, with clear pull toward immunology, oncology, cell/immune-evasive therapies, and rare/severe disease — consistent with his immunology PhD.
• Check sizes reported in the ~$100K–$10M range, with a typical sweet spot near $5M, reflecting F-Prime's ability to lead early rounds and follow on.
• Looks for strong underlying science plus a credible development and business-building plan — a lens sharpened by his McKinsey work advising pharma/medtech on BD, R&D, and strategy.
• As part of F-Prime, favors founding/company-creation and lead-investor roles in novel therapeutic platforms rather than late-stage or generalist tech deals.